New PNH drug trial aims to boost red blood cells in patients with persistent anemia
NCT ID NCT06848296
First seen May 08, 2026 · Last updated May 08, 2026
Summary
This early-stage study tests a new drug called VSA012 in about 50 adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder. The goal is to see if the drug is safe and can improve red blood cell levels in patients who still have anemia despite current treatments. Participants either have not used complement inhibitors before or have persistent anemia after stable use of a C5 inhibitor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
-
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.